Medicinal cannabis studies

The CMOS Study is an observational study that will be run in collaboration with GP’s and specialists around Australia. This study aims to recruit 20,000 Australian patients undergoing treatment with medicinal cannabis.

The CMOS Study will benefit participating clinicians, and their patients, by providing insight into medicinal cannabis prescribing and treatment practices from clinics around Australia participating in CMOS. Insights will be provided in the form of de-identified aggregated data reports including information on product dosing/categories being prescribed, patient reported outcomes (PROs) and adverse events reported by study participants, to be released to participating clinics on a quarterly basis. This data will provide a useful resource for clinicians who may be prescribing medicinal cannabis products and wish to gain better insight into the current Australian prescribing landscape.

Study Name: Cannabinoid Medicine Observational Study (CMOS)

Study Type: Observational

Objective: Collect data about safety and efficacy of medicinal cannabis products in treatment of refractory indications, as well as data on effective dosage and effects of medicinal cannabis treatment on concomitant medication use.

Indications Assessed: The CMOS study will encompass a range of refractory conditions, including but not limited to: chronic pain conditions, neurological disorders, cancer pain and symptom management, psychiatric disorders, sleep disorders, palliative care, inflammatory conditions, gastrointestinal disorders, movement disorders and respiratory conditions.

Enrolment: Patients will be able to be enrolled in the study directly by their treating clinician (GP or specialist)

Eligibility Criteria:
– Deemed suitable for medicinal cannabis treatments by an Australian registered GP or specialist
– Willing and able to provide informed consent

The CMOS study is planning to launch in Q3 2020. To register interest in becoming a participating doctor/clinic please see here.